Compugen Ltd. Company Profile
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugen's growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) 'discovery on demand' agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by a partner. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN), to utilize certain of the Company's 'in silica' predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at: www.cgen.com.
News Articles
BMS invests $12m in cancer immunotherapy tie-up with Compugen
Bristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could boost the effectiveness of its blockbuster cancer immunotherapy Opdivo. BMS said i...
Bristol-Myers, Compugen To Jointly Evaluate Combination Of COM701 With Opdivo
NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and Compugen (CGEN) announced a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investiga...
Compugen earns $7.8m payment from Bayer
The continued development of cancer drug BAY 1905254 is a major boost for Compugen's ability to successfully identify new mechanisms for treatments using its big data systems.
BMS to invest in, collaborate with Compugen
Bristol-Myers Squibb and Israel-based Compugen said they will collaborate in clinical trials for patients with advanced solid tumors.
BMS invests $12m in Compugen for tumor collaboration
The companies have entered into a clinical trial collaboration to evaluate Compugen’s COM701 with BMS's PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors.
BMS, Compugen Pursue Multiple Checkpoint Inhibitions In Antibody Collaboration
Bristol-Myers Squibb is teaming up with Compugen to test the latter’s investigational antibody that targets a new checkpoint, PVRIG, in...
Compugen doses first patient in Phase l trial of COM701
Compugen has dosed the first patient in a Phase l clinical trial of COM701 for the treatment of patients with...Read More... The post Compugen doses first patient in Phase l trial of COM701 appeared f...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are b...
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based...
Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology ...
Neviah Genomics was jointly established in 2012 by Merck Serono, the biopharmaceutical business of Merck, and Compugen Ltd. The company operates out of the MS Venturesâ Israe...
BioLineRx Ltd. and Compugen Ltd.
BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over curr...
More Information about "Compugen Ltd." on BioPortfolio
We have published hundreds of Compugen Ltd. news stories on BioPortfolio along with dozens of Compugen Ltd. Clinical Trials and PubMed Articles about Compugen Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Compugen Ltd. Companies in our database. You can also find out about relevant Compugen Ltd. Drugs and Medications on this site too.
